Feasibility of chemosensitivity testing in soft tissue sarcomas

World Journal of Surgical Oncology

Volumn 3, Issue , 2005, Pages

  Lehnhardt, Marcus ^a   Muehlberger, Thomas ^a   Kuhnen, Cornelius ^b   Brett, Daniel ^a   Steinau, Hans U ^a   Jafari, Hamid Joneidi ^a   Steinstraesser, Lars ^a   Müller , Oliver ^c   Homann, Heniz H ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

Author keywords

ATP TCA; Chemosensitivity; Chemotherapy; Soft tissue sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; LUCIFERASE; LUCIFERIN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CELL DIFFERENTIATION; CHEMOLUMINESCENCE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; RECURRENT CANCER; SOFT TISSUE SARCOMA;

EID: 27444437913     PISSN: 14777819     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-3-20     Document Type: Article

References (51)

1. Singer S, Demetri GD, Baldini EH, Fletcher CD: Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 2000, 1:75-85.
2. Reichardt P: High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 2002, 41:157-167.
3. Steinau HU, Homann HH, Drucke D, Torres A, Soimaru D, Vogt P: [Resection method and functional restoration in soft tissue sarcomas of the extremities]. Chirurg 2001, 72:501-513.
4. Chao C, McMasters KM, Edwards MJ: Advances in the treatment of soft-tissue sarcomas. J Ky Med Assoc 2002, 100:10-16.
5. Donato Di Paola E, Nielsen OS: The EORTC soft tissue and bone sarcoma group. Eur J Cancer 2002, 38 Suppl 4:S138-S141.
6. Frustaci S, Foladore S, Buonadonna A, De Paoli A, Crivellari D, Carbone A, Sorio R, Morassut S, Monfardini S: Epirubicin and ifosfamide in advanced soft tissue sarcomas. Ann Oncol 1993, 4:669-672.
7. Frustaci S, De Paoli A, Bidoli E, La Mura N, Berretta M, Buonadonna A, Boz G, Gherlinzoni F: Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003, 65:80-84.
8. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001, 19:1238-1247.
9. Bui BN, Tabrizi R, Dagada C, Trufflandier N, St ckle E, Coindre JM: [Update on soft tissue sarcomas]. Bull Cancer 2002, 89:100-107.
10. Demetri GD: ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 2002, 13 Suppl 1:S7-9.
11. Ryan DP, Puchalski T, Supko JG, Harmon D, Maki R, Garcia-Carbonero R, Kuhlman C, Winkelman J, Merriam P, Quigley T, Jimeno J, Manola J, Demetri GD: A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 2002, 7:531-538.
12. van Oosterom AT, Verweij J: New drugs for the treatment of sarcomas. Hematol Oncol Clin North Am 1995, 9:909-925.
13. Reichardt P, Oechsle K, Pink D, Bokemeyer C, Schneller F, Issels R, Kanz L, Hartmann JT: An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 2003, 21:481-486.
14. Budd GT, Rankin C, Hutchins LF, Wong L, Petruska PJ, Antman K: Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group. Invest New Drugs 2002, 20:129-132.
15. Ruymann FB, Grovas AC: Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest 2000, 18:223-241.
16. Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001, 7:231-242.
17. Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, van Glabbeke M, Verweij J, Hogendoorn PC, Nielsen OS: Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002, 38:556-559.
18. Kurbacher CM, Mallmann P, Kurbacher JA, Hubner H, Krebs D: Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay. Geburtshilfe Frauenheilkd 1996, 56:70-78.
19. Untch M, Sevin BU, Untch A, Konecny G, Nestle-Kramling C, Korell M, Hepp H: [Testing chemosensitivity of cancer cell lines and gynecologic tumors with the ATP assay]. Gynakol Geburtshilfliche Rundsch 1993, 33:311-313.
20. Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN: The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs 1997, 8:756-762.
21. Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janat MM, Untch M, Konecny G, Bruckner HW, Cree IA: ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Recent Results Cancer Res 2003, 161:221-230.
22. Untch M, Ditsch N, Langer E, Kurbacher C, Crohns C, Konecny G, Kahlert S, Bauerfeind I, Hepp H: Chemosensitivity testing in gynecologic oncology - dream or reality? Recent Results Cancer Res 2003, 161:146-158.
23. Whitehouse PA, Mercer SJ, Knight LA, Di Nicolantonio F, O'Callaghan A, Cree IA: Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C. Br J Cancer 2003, 89:2299-2304.
24. Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Di Nicolantonio F, Glaysher S, Toh S, Cree IA: Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. Anticancer Drugs 2003, 14:397-403.
25. Sharma S, Neale MH, Nicolantonio DF, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM, Cree IA: Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 2003, 3:19.
26. Whitehouse PA, Knight LA, Di Nicolantonio F, Mercer SJ, Sharma S, Cree IA: Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Anticancer Drugs 2003, 14:369-375.
27. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, et al.: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995, 55:5276-5282.
28. Morioka H, Yabe H, Morii T, Yamada R, Kato S, Yuasa S, Yano T: In vitro chemosensitivity of human soft tissue sarcoma. Anticancer Res 2001, 21:4147-4151.
29. Cree IA, Kurbacher CM: ATP-based tumor chemosensitivity testing: assisting new agent development. Anticancer Drugs 1999, 10:431-435.
30. Rouesse J, Tubiana-Hulin M: [Chemotherapy of sarcomas in the adult]. Bull Cancer 1988, 75:483-492.
31. DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, Rosenberg AL, Rosenthal DI, Miryousefi F, Ancukiewicz M, Harmon DC: Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003, 56:1117-1127.
32. Mori S, Apice G, Ottaiano A, De Chiara A, Germano A, Botti G, De Rosa V, Ravo V, Morrica B, Mozzillo N: [Role of neoadjuvant chemotherapy in intermediate/high-grade soft-tissue sarcomas in the adult]. Tumori 2003, 89:267-268.
33. Gravis G, Mousseau M, Douillard JY, Dorval T, Fabbro M, Escudier B, Mignot L, Viens P: Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial. Eur Cytokine Netw 2001, 12:239-243.
34. Gravis G, Viens P, Delva R, Baume D, Blaise D, Ternier F, Houvenaeghel G, Brandely M, Resbeut M, Maraninchi D: rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: response and enhancement of further chemosensitivity. Anticancer Res 1998, 18:3699-3704.
35. Le Cesne A: [Chemotherapy of metastatic soft tissue sarcoma]. Presse Med 1995, 24:1214-1220.
36. van Haelst-Pisani CM, Buckner JC, Reiman HM, Schaid DJ, Edmonson JH, Hahn RG: Does histologic grade in soft tissue sarcoma influence response rate to systemic chemotherapy? Cancer 1991, 68:2354-2358.
37. Bramwell VH, Anderson D, Charette ML: Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003:CD003293.
38. Koscielniak E, Harms D, Henze G, Jurgens H, Gadner H, Herbst M, Klingebiel T, Schmidt BF, Morgan M, Knietig R, Treuner J: Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 1999, 17:3706-3719.
39. Koscielniak E, Morgan M, Treuner J: Soft tissue sarcoma in children: prognosis and management. Paediatr Drugs 2002, 4:21-28.
40. Ruymann FB: The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore? Curr Oncol Rep 2003, 5:505-509.
41. Lehti PM, Moseley HS, Janoff K, Stevens K, Fletcher WS: Improved survival for soft tissue sarcoma of the extremities by regional hyperthermic perfusion, local excision and radiation therapy. Surg Gynecol Obstet 1986, 162:149-152.
42. Phan A, Patel S: Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol 2003, 4:433-439.
43. Cartei G, Clocchiatti L, Sacco C, Pella N, Bearz A, Mantero J, Pastorelli D, Salmaso F, Zustovich F: Dose finding of ifosfamide administered with a chronic two-week continuous infusion. Oncology 2003, 65:31-36.
44. Schlemmer M, Wendtner CM, Issels RD: Ifosfamide with regional hyperthermia in soft-tissue sarcomas. Oncology 2003, 65:76-79.
45. Wall N, Starkhammar H: Chemotherapy of soft tissue sarcoma - a clinical evaluation of treatment over ten years. Acta Oncol 2003, 42:55-61.
46. Gottlieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JPJ, Sinkovics JG, Rivkin SE, Brownlee R, Frei E: Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 1972, 30:1632-1638.
47. Issels RD, Schlemmer M: Current trials and new aspects in soft tissue sarcoma of adults. Cancer Chemother Pharmacol 2002, 49 Suppl 1:S4-8.
48. Wendtner C, Abdel-Rahman S, Baumert J, Falk MH, Krych M, Santl M, Hiddemann W, Issels RD: Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer 2001, 37:1609-1616.
49. Issels RD, Abdel-Rahman S, Wendtner C, Falk MH, Kurze V, Sauer H, Aydemir U, Hiddemann W: Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer 2001, 37:1599-1608.
50. Hoos A, Lewis JJ, Brennan MF: [Soft tissue sarcoma: prognostic factors and multimodal treatment]. Chirurg 2000, 71:787-794.
51. Wang Y, Liu S, Mo S: [Management and prognosis of patients with locally recurrent soft tissue sarcomas]. Zhonghua Zhong Liu Za Zhi 1997, 19:231-234.